GU Cancers 2022 | The need for biomarkers to aid in treatment decision making for upper tract urothelial carcinoma

Janet Kukreja, MD, MPH, University of Colorado, Boulder, CO, outlines the requirement for biomarkers in upper tract urothelial carcinoma (UTUC) due to the difficulties in making a correct diagnosis for different types of UTUC tumors. Historically, UTUC has been treated as bladder cancer despite being gnomically different. The discovery of UTUC biomarkers would aid in the differentiation of treatment and the personalization of medicine. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.